YM155

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Melanoma

Conditions

Melanoma

Trial Timeline

Nov 1, 2005 → Jun 1, 2007

NCT ID

NCT00281541

About YM155

YM155 is a phase 2 stage product being developed by Astellas Pharma for Melanoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00281541. Target conditions include Melanoma.

What happened to similar drugs?

4 of 20 similar drugs in Melanoma were approved

Approved (4) Terminated (2) Active (14)

✅dabrafenib + trametinibNovartisApproved

✅ZelborafRocheApproved

✅Nivolumab + RelatlimabBristol Myers SquibbApproved

✅Fibrin Sealant (Tisseel) used in the Experimental Arm.BaxterApproved

❌Tasisulam-sodium + PaclitaxelEli LillyPhase 3

🔄Pembrolizumab + Lenvatinib + Placebo for lenvatinibEisaiPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00257478	Phase 2	Completed	—	Mar 1, 2007	Prostate Cancer
NCT01023386	Phase 1	Completed	Nov 1, 2009	Mar 1, 2010	Cancer
NCT00498914	Phase 2	Terminated	Jun 1, 2007	Apr 1, 2009	Lymphoma, Large-Cell, Diffuse
NCT00328588	Phase 2	Completed	Dec 1, 2006	Mar 1, 2007	Lung Cancer
NCT00818480	Phase 2	Completed	Feb 1, 2006	Aug 1, 2012	Prostate Cancer
NCT00281541	Phase 2	Completed	Nov 1, 2005	Jun 1, 2007	Melanoma

Competing Products

20 competing products in Melanoma

See all competitors

Product	Company	Stage	Hype Score
mRNA-4157 + Pembrolizumab	Merck	Phase 2	39
AVT32-DRL_PB + Keytruda	Dr. Reddy's Laboratories	Phase 1	33
Binimetinib Oral Tablet	Biotrial	Phase 1	15
Tasisulam-sodium + Paclitaxel	Eli Lilly	Phase 3	32
[203Pb]VMT01 + [212Pb]VMT01 + Nivolumab	Perspective Therapeutics	Phase 1/2	33
[203Pb]VMT01 + [68Ga]VMT02	Perspective Therapeutics	Phase 1	23
FYB206 + Keytruda	Formycon AG	Phase 1	23
PLX3397	Daiichi Sankyo	Pre-clinical	26
PLX3397 + Pembrolizumab	Daiichi Sankyo	Phase 1/2	24
Trastuzumab deruxtecan	Daiichi Sankyo	Phase 2	39
DS-8273a + Nivolumab	Daiichi Sankyo	Phase 1	29
PLX3397 + vemurafenib	Daiichi Sankyo	Phase 1	21
enfortumab vedotin + pembrolizumab	Astellas Pharma	Phase 2	42
CP-461	Astellas Pharma	Phase 2	27
YM155 + Docetaxel	Astellas Pharma	Phase 2	35
Denileukin diftitox	Eisai	Phase 2	35
E7080	Eisai	Phase 1	29
lenvatinib + pembrolizumab	Eisai	Phase 2	35
MORAb-004 (monoclonal antibody)	Eisai	Phase 2	35
Pembrolizumab + Lenvatinib	Eisai	Phase 2	39